Cover Image
市場調查報告書

PharmaPoint:克隆氏症 - EU5個國家的醫藥品預測與市場分析

PharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022

出版商 GlobalData 商品編碼 298052
出版日期 內容資訊 英文 168 Pages
訂單完成後即時交付
價格
Back to Top
PharmaPoint:克隆氏症 - EU5個國家的醫藥品預測與市場分析 PharmaPoint: Crohn's Disease - 5EU Drug Forecast and Market Analysis to 2022
出版日期: 2014年01月31日 內容資訊: 英文 168 Pages
簡介

克隆氏症(CD)治療藥市場由於新生物療法的出現而非常活絡。由於抗TBF上市藥專利的到期,造成新興生技仿製藥的興起。譬如Remicade的生技仿製藥、Hospira的Inflectra(infliximab)等。

本報告提供EU5個國家的克隆氏症(CD)治療藥市場相關調查分析,提供疾病的概要與指南,競爭情形,主要藥物的詳細資訊(產品說明,安全性,有效性),彙整SWOT分析,銷售額預測,影響分析(趨勢,推動因素·阻礙因素)等,為您概述為以下內容。

第1章 目錄

第2章 簡介

第3章 疾病概要

  • 病因·病理生理學
    • 病因
    • 病理生理學
  • 症狀
  • 預測
  • 生活品質(QOL)

第4章 疾病的管理

  • 治療概要
  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第5章 競爭評估

  • 概要
  • 策略性競爭企業的評估
  • 產品簡介 - 領導品牌
  • 生技仿製藥

第6章 機會及未滿足需求

  • 概要
  • 個別治療用生物標記的需求
  • 抗TNF難治型患者的治療
  • 未滿足需求的差距分析
  • 標靶治療
  • 早期診斷·治療的預測工具

第7章 開發平台評估

  • 概要
  • 臨床開發中的潛力藥物
  • 其他後期開發中產品

第8章 市場預測

  • 全球市場

第9章 EU5個國家

  • 法國
  • 德國
  • 義大利
  • 西班牙
  • 英國

第10章 附錄

圖表

目錄
Product Code: GDHC209CFR

The Crohn's disease (CD) market is currently very dynamic, with novel biologic therapies on the horizon. These compounds will challenge the current biologics in an attempt to dislodge the stronghold of the TNF inhibitors, as they aim to tap into the lucrative portion of the CD therapeutics market. If their promising safety and efficacy profiles translate to clinical practice once they enter the market, their launch will be to the detriment of the existing market leaders, Remicade (infliximab) and Humira (adalimumab).The loss of patent protection of the anti-TNF marketed brands will allow for the emergence of biosimilars, such as Hospira's Inflectra (infliximab) a Remicade biosimilar. Focusing on country dynamics, Canada and the emerging markets of China and India will also play a key role in driving growth in the long term, with each market forecast to post positive Compound Annual Growth Rates (CAGRs) from 2012 to 2022, primarily due to the anticipated strong uptake of Remicade over the forecast period.

In general, US and Canadian gastroenterologists follow the treatment guidelines published by the American College of Gastroenterology (ACG) and the American Gastroenterology Association (AGA), while physicians in the EU mainly rely on the European Crohn's and Colitis Organisation (ECCO) guidelines. Outside these regions, Japanese gastroenterologists consult the guidelines published by the MHLW, while their colleagues in China and India adhere to the guidelines published by the ACG and the AGA, in addition to the guidelines issued by local medical authorities.

Scope

  • Overview of Crohn's disease including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in the 5 EU countries including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in the 5 EU countries from 2012-2022.
  • Analysis of the impact of key events as well the drivers and restraints affecting the 5 EU Crohn's disease market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return.
  • Stay ahead of the competition by understanding the changing competitive landscape for Crohn's disease..
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential.
  • Make more informed business decisions from insightful and in-depth analysis of drug performance.
  • Obtain sales forecast for drugs from 2012-2022 in the 5EU countries.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Catalyst
  • 2.2. Related Reports
  • 2.3. Upcoming Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Symptoms
  • 3.3. Prognosis
  • 3.4. Quality of Life

4. Disease Management

  • 4.1. Treatment Overview
  • 4.2. France
    • 4.2.1. Diagnosis
    • 4.2.2. Clinical Practice
  • 4.3. Germany
    • 4.3.1. Diagnosis
    • 4.3.2. Clinical Practice
  • 4.4. Italy
    • 4.4.1. Diagnosis
    • 4.4.2. Clinical Practice
  • 4.5. Spain
    • 4.5.1. Diagnosis
    • 4.5.2. Clinical Practice
  • 4.6. UK
    • 4.6.1. Diagnosis
    • 4.6.2. Clinical Practice

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Strategic Competitor Assessment
  • 5.3. Product Profiles - Major Brands
    • 5.3.1. Remicade (infliximab)
    • 5.3.2. Humira (adalimumab)
    • 5.3.3. Cimzia (certolizumab pegol)
    • 5.3.4. Tysabri (natalizumab)
    • 5.3.5. Other Marketed Products
  • 5.4. Biosimilars
    • 5.4.1. Introduction
    • 5.4.2. Hospira's Inflectra Versus J&J's Remicade in Key Autoimmune Diseases
    • 5.4.3. Biosimilars in the Immunology Community
    • 5.4.4. By the Numbers: Biosimilars in Development
    • 5.4.5. The Impact of Biosimilars Will be Felt Through out the Pharmaceutical Industry

6. Opportunity and Unmet Need

  • 6.1. Overview
  • 6.2. Physicians Desire Biomarkers That Will Allow a Personalized Treatment Approach
  • 6.3. More Therapies for Anti-TNF-Refractory Patients
  • 6.4. Unmet Needs Gap Analysis
  • 6.5. Targeted Therapies
  • 6.6. Predictive Tools for Early Diagnosis and Treatment

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Promising Drugs in Clinical Development
    • 7.2.1. Entyvio (vedolizumab)
    • 7.2.2. Stelara (ustekinumab)
    • 7.2.3. Vercirnon (formerly GSK1605786)
  • 7.3. Other Late-Stage Pipeline Products
    • 7.3.1. Cx601
    • 7.3.2. RHB-104 (clarithromycin + clofazimine + rifabutin)

8. Market Outlook

  • 8.1. Global Markets
    • 8.1.1. Drivers and Barriers - Global Issues

9. 5. EU

  • 9.1. France
    • 9.1.1. Forecast
    • 9.1.2. Key Events
    • 9.1.3. Drivers and Barriers
  • 9.2. Germany
    • 9.2.1. Forecast
    • 9.2.2. Key Events
    • 9.2.3. Drivers and Barriers
  • 9.3. Italy
    • 9.3.1. Forecast
    • 9.3.2. Key Events
    • 9.3.3. Drivers and Barriers
  • 9.4. Spain
    • 9.4.1. Forecast
    • 9.4.2. Key Events
    • 9.4.3. Drivers and Barriers
  • 9.5. UK
    • 9.5.1. Forecast
    • 9.5.2. Key Events
    • 9.5.3. Drivers and Barriers

10. Appendix

  • 10.1. Bibliography
  • 10.2. Abbreviations
  • 10.3. Methodology
  • 10.4. Forecasting Methodology
    • 10.4.1. Diagnosed CD Patients
    • 10.4.2. Percent Drug-Treated Patients
    • 10.4.3. Drugs Included in Each Therapeutic Class
    • 10.4.4. Launch and Patent Expiry Dates
    • 10.4.5. General Pricing Assumptions
    • 10.4.6. Individual Drug Assumptions
    • 10.4.7. Generic Erosion
    • 10.4.8. Pricing of Pipeline agents
  • 10.5. Physicians and Specialists Included in This Study
  • 10.6. Primary Research - Prescriber Survey
  • 10.7. About the Authors
    • 10.7.1. Author/Reviewer
    • 10.7.2. Global Head of Healthcare
  • 10.8. About GlobalData
  • 10.9. Disclaimer

List of Tables

  • Table 1: Symptoms of CD
  • Table 2: Treatment Guidelines for CD
  • Table 3: Most Commonly Prescribed Drugs for CD in the Global Markets by Disease Severity, 2013
  • Table 4: Leading Branded Drugs Used to Treat CD
  • Table 5: Product Profile - Remicade
  • Table 6: Remicade SWOT Analysis, 2013
  • Table 7: Product Profile - Humira
  • Table 8: Humira SWOT Analysis, 2013
  • Table 9: Product Profile - Cimzia
  • Table 10: Cimzia SWOT Analysis, 2013
  • Table 11: Product Profile - Tysabri
  • Table 12: Tysabri SWOT Analysis, 2013
  • Table 13: Summary of the Minor Therapeutic Classes in CD, 2013
  • Table 14: Biosimilars Pipeline, 2013
  • Table 15: Overall Unmet Needs in CD - Current Level of Attainment
  • Table 16: Clinical Unmet Needs in CD - Gap Analysis, 2013
  • Table 17: Promising Drugs in Clinical Development for CD - Pipeline Phase, 2013
  • Table 18: Comparison of Therapeutic Classes in Development for CD, 2013
  • Table 19: Product Profile - Entyvio
  • Table 20: Efficacy of Entyvio in GEMINI II Studies of CD
  • Table 21: Entyvio SWOT Analysis, 2013
  • Table 22: Product Profile - Stelara
  • Table 23: Comparison of Stelara's Phase IIb CERTIFI trial Efficacy Data Versus Tysabri's Phase III Efficacy Data in Anti-TNF Refractory CD Patients
  • Table 24: Stelara SWOT Analysis, 2013
  • Table 25: Product Profile - Vercirnon
  • Table 26: Vercirnon SWOT Analysis, 2013
  • Table 27: Product Profile - Cx601
  • Table 28: Cx601 SWOT Analysis, 2013
  • Table 29: Product Profile - RHB-104
  • Table 30: RHB-104 SWOT Analysis, 2013
  • Table 31: Global CD Market - Drivers and Barriers, 2012-2022
  • Table 32: Sales Forecasts ($) for CD in France, 2012-2022
  • Table 33: Key Events Impacting Sales for CD in France, 2012-2022
  • Table 34: CD Market in France - Drivers and Barriers, 2012-2022
  • Table 35: Sales Forecasts ($) for CD in Germany, 2012-2022
  • Table 36: Key Events Impacting Sales for CD in Germany, 2012-2022
  • Table 37: CD Market in Germany - Drivers and Barriers, 2012-2022
  • Table 38: Sales Forecasts ($) for CD in Italy, 2012-2022
  • Table 39: Key Events Impacting Sales for CD in Italy, 2012-2022
  • Table 40: CD Market in Italy - Drivers and Barriers, 2012-2022
  • Table 41: Sales Forecasts ($) for CD in Spain, 2012-2022
  • Table 42: Key Events Impacting Sales for CD in Spain, 2012-2022
  • Table 43: CD Market in Spain - Drivers and Barriers, 2012-2022
  • Table 44: Sales Forecasts ($) for CD in the UK, 2012-2022
  • Table 45: Key Events Impacting Sales for CD in the UK, 2012-2022
  • Table 46: CD Market in the UK - Drivers and Barriers, 2012-2022
  • Table 47: Key Launch Dates
  • Table 48: Key Patent Expiries
  • Table 49: Physicians Surveyed, By Country

List of Figures

  • Figure 1: Mucosa of the Bowel in a Healthy Individual (Left) and a Patient With CD (Right)
  • Figure 2: Potential Biologic Drug Targets for CD
  • Figure 3: Patient Care Path for CD
  • Figure 4: Competitive Assessment of Late-Stage Pipeline Agents in CD, 2012-2022
  • Figure 5: Sales for CD in France by Drug Class, 2012-2022
  • Figure 6: Sales for CD in Germany by Drug Class, 2012-2022
  • Figure 7: Sales for CD in Italy by Drug Class, 2012-2022
  • Figure 8: Sales for CD in Spain by Drug Class, 2012-2022
  • Figure 9: Sales for CD in the UK by Drug Class, 2012-2022
Back to Top